Colorectal cancer remains one of the leading causes of cancer-related mortality worldwide. Recent advancements in immunotherapy have demonstrated the potential of targeting immune checkpoints and co-inhibitory pathways to enhance antitumor responses.
Acute myeloid leukemia (AML) is an aggressive blood cancer characterized by the accumulation of immature myeloid cells. Current treatments often fail to achieve durable remission, underscoring the need for innovative therapeutic approaches. CD97 is a cell surface protein with broad, increased expression on AML cells compared to normal blood stem and progenitor cells. Moreover, CD97 overexpression in AML patients has been associated with poor survival, thus emerging as a potential therapeutic target.
Pancreatic ductal adenocarcinoma (PDAC) is a type of cancer characterized by very poor prognosis and resistance to immunotherapy due to an immunosuppressive tumor microenvironment, which includes extensive desmoplasia and a dense stroma.
Epimab Biotherapeutics Inc. licensed out a development-ready KLK2/CD3 bispecific T-cell engager (TCE) for advanced prostate cancer to Juri Biosciences Inc. through a potential $210 million deal.
LIN28 is a family of RNA-binding proteins that regulate stem cell biology and pluripotency and are involved in oncogenesis through the interaction with tumor suppressor microRNA let-7. The expression of LIN28 leads to the loss of function of let-7, leading to tumorigenesis, and has been tied to tumor aggressiveness and poor survival in children with brain tumors.
Interferon (IFN)-α, on paper, should be quite effective against hepatocellular carcinoma, the most frequent form of primary liver cancer. IFN-α can suppress tumor growth directly by acting on tumor cells, as well as indirectly by activating cytotoxic CD8+ T cells. In addition, it can slow replication of hepatitis B virus, which is involved in 50% to 80% of cases of hepatocellular carcinoma. However, IFN-α on its own has performed disappointingly in clinical trials.
RSS
